Anti-CD19 CAR T cell therapy for lymphoma — off to the races!

Anti-CD19 CAR T cell therapy for lymphoma — off to the races!Anti-CD19 CAR T cell therapy for lymphoma — off to the races!, Published online: 27 February 2019; doi:10.1038/s41571-019-0183-7Recently published data from the ZUMA-1 and JULIET trials suggest that CD19-directed chimeric antigen receptor (CAR) T cell therapy can provide durable remissions, with a low risk of relapse or progression, in 30–40% of patients with relapsed and/or refractory aggressive large B cell lymphoma. Two-year follow-up of the ZUMA-1 clinical trial has not revealed any unexpected toxicities, but further safety monitoring will be needed.

Source: Nature Clinical Practice Oncology - February 27, 2019 Category: Cancer & Oncology Authors: David G. Maloney Source Type: research